Atropos Health, a health tech company focusing on personalized real-world evidence for care, has secured USD 33 million in Series B funding. The round was led by Valtruis, and contributions from other venture capital firms brought the total funds raised by the company to USD 47 million.
The company intends to use the raised funds to amplify its stake in value-based care. Specifically, it plans to fuel its work in GenAI capabilities, scaling the automation of generating personalized real-world data. Additionally, the company plans to secure partnerships with pharmaceutical and vertically integrated healthcare companies to drive evidence adoption in oncology and other specialty areas.
Post funding Mike Spadafore, a value-based care veteran, joined Atropos’ board of directors.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.